Equillium (EQ) Expected to Release Quarterly Earnings on Thursday

Equillium (NASDAQ:EQ) is anticipated to announce its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 18, 2026 at 4:00 PM ET.

Equillium (NASDAQ:EQ) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01. On average, analysts expect Equillium to post ($0.21) EPS for the current fiscal year and ($0.24) EPS for the next fiscal year.

Equillium Stock Down 0.7%

Shares of NASDAQ EQ opened at $1.50 on Tuesday. Equillium has a twelve month low of $0.76 and a twelve month high of $3.54. The firm has a fifty day simple moving average of $1.66 and a 200 day simple moving average of $2.08. The company has a market capitalization of $95.11 million, a PE ratio of -7.50 and a beta of 2.08.

Wall Street Analysts Forecast Growth

EQ has been the subject of a number of recent analyst reports. Wall Street Zen downgraded Equillium from a “hold” rating to a “sell” rating in a report on Saturday, September 19th. Roth Capital reissued a “buy” rating on shares of Equillium in a research report on Monday, October 26th. Piper Sandler assumed coverage on Equillium in a research note on Monday, July 13th. They issued an “overweight” rating on the stock. Clear Str raised Equillium to a “strong-buy” rating in a research note on Tuesday, July 21st. Finally, Zacks Research upgraded Equillium from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Equillium presently has an average rating of “Moderate Buy” and a consensus price target of $7.57.

About Equillium

Equillium, Inc is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company seeks to address immune-system dysregulation by developing treatments that selectively modulate immune-cell activity rather than broadly suppressing the immune system.

Equillium’s lead product candidate is itolizumab, a monoclonal antibody that targets CD6, a protein involved in the activation and trafficking of certain T cells. The company has evaluated itolizumab in conditions including acute graft-versus-host disease and lupus nephritis.